The potential place of tenofovir in antiretroviral treatment regimens

International Journal of Clinical Practice

Volumn 55, Issue 10, 2001, Pages 704-709

  Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; CIDOFIVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENSING; LIPODYSTROPHY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035668423     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Concorde trial of immediate versus deferred zidovudine
3. The Delta trial
4. A controlled trial of two nucleoside analogues plus indinavir in persons with immunodeficiency virus infection and CD4 counts of 200 per cubic mm or more
5. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
6. Time to treat HIV early and hard
7. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
8. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
9. Adverse effects of antiretroviral therapy
10. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
11. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
12. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (the living document)
13. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
14. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
15. ABT-378/ritonavir (BT-378/r) versus nelfinavir in antiretroviral naive subjects: Week 48 comparison in a phase III blinded randomised clinical trial
16. Evaluation of ABT-378/ritonavir (ABT-378/r) based salvage regimens in a cohort of HIV-infected patients
17. A controlled phase II trial assessing three doses of T20 in combination with abacavir, amprenavir, low dose of ritonavir and efavirenz in non-nucleoside naive protease inhibitor experienced HIV-1 infected adults
18. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA
19. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β and γ
20. Antiretroviral activities of PMPA against various drug resistant immunodeficient viral strains
21. Tenofovir (PMPA) is less efficiently removed through pyrophosphorolysis and dinucleotide polyphosphate synthesis than zidovudine (AZT) by HIV-1 wild-type RT and RT mutants
22. HIV-1 RT mutations in patients after 24 weeks of tenofovir disoproxil fumarate (formerly PMPA prodrug) therapy added to stable background ART
23. Tenofovir DF. A 24 week interim analysis from a Phase III double blind placebo controlled study in antiretroviral experienced patients
24. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized double-blind trial
25. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1